Open-label extension of two phase 3 trials in relapsing MS (851 included): annualised relapse rate fell 58.4% in the year after switching from teriflunomide to ublituximab; year-5 24-week disability progression was 8.0% with continuous ublituximab vs 14.3% after switching.
RCTn = 851
Cree et al. Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study